Latest on Anabolic Agents for Osteoporosis Treatment

• Filippo, Luigi di ^[1] ; Rosen, Clifford J. ^[2]
  1. [1] Institute of Endocrine and Metabolic Sciences, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
  2. [2] Center for Clinical and Translational Research, MaineHealth Institute for Research, Scarborough, ME 04074, USA
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 53, Nº. 4, 2024 (Ejemplar dedicado a: Updates on Osteoporosis Diagnosis and Therapy), págs. 513-523
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • The efficacies of anabolic compounds in preventing fragility fractures and increasing BMD were progressively and widely demonstrated in the last decades. Latest updated clinical data (Table 1) in this setting have markedly downgrading their potential serious side effects including risk of malignancies in teriparatide- and cardiovascular events in romosozumab-users, respectively. Further future data are warranted about their potential efficacy in patients with GIO and, interestingly, their use...